Dyspnoea and hyperventilation induced by synthetic progesterone chlorpromadinone acetate for the treatment of prostatic hypertrophy.
We describe a 74-year-old patient with dyspnoea and tachypnoea induced by chlorpromadinone acetate, a synthetic progesterone used to treat prostatic hyperplasia. The dyspnoea, tachypnoea and hypocapnia improved after discontinuing the chlorpromadinone acetate. It is important to recognize that synthetic progesterones can cause dyspnoea and hyperventilation.
Fujii
K
K
First Department of Internal Medicine, Kumamoto University School of Medicine, Kumamoto, Japan.
Kohrogi
H
H
Hirosako
S
S
Kawano
O
O
Hirata
N
N
Goto
E
E
Ando
M
M
D000085:Acetates / Q000009:adverse effects* / Q000627:therapeutic use; D000368:Aged; D001784:Blood Gas Analysis; D004417:Dyspnea / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D006985:Hyperventilation / Q000139:chemically induced* / Q000503:physiopathology; D008297:Male; D045167:Progesterone Congeners / Q000009:adverse effects* / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D012129:Respiratory Function Tests
D000085:Acetates; D045167:Progesterone Congeners; C438306:chlorpromadinone acetate